MedinCell: Videoconference and Publication of Financial Results for 2022-2023 on June 26th, 2023
20 Giugno 2023 - 6:30PM
Business Wire
Regulatory News:
MedinCell (Paris:MEDCL) will hold a videoconference on Monday
June 26, 2023 at 6:30 pm to present the 2022-2023 annual results
for the year ending on March 31st, 2023.
> To watch the meeting in French :
https://www.medincell.com/fr/investisseurs/#events >
To watch the meeting in English :
https://www.medincell.com/en/investors/#events
The company's management will answer shareholders' questions,
which can be sent to communication@medincell.com, or asked live
during the video conference.
About MedinCell
MedinCell is an innovative pharmaceutical company developing a
portfolio of long-acting injectable products in various therapeutic
areas - from development to commercialization - by combining its
proprietary BEPO® technology (licensed to Teva under the name
SteadyTeq™) with active ingredients already known and marketed.
Through the controlled and extended release of the active
pharmaceutical ingredient, MedinCell makes medical treatments more
efficient, particularly thanks to improved compliance and to a
significant reduction in the quantity of medication required.
MedinCell's proprietary BEPO technology makes it possible to
control the delivery of a drug at a therapeutic dose for several
days, weeks or months, from the subcutaneous or local injection of
a simple, fully bioresorbable deposit just a few millimeters in
size. The first treatment based on BEPO technology for the
treatment of schizophrenia was approved by the FDA in April 2023
and is now commercialized in the United States by Teva under the
name UZEDY™. MedinCell collaborates with leading pharmaceutical
companies and foundations to improve global health through new
therapeutic options. Based in Montpellier, MedinCell currently
employs over 140 people representing more than 25 different
nationalities. www.medincell.com
UZEDY™ and SteadyTeq™ are trademarks of Teva Pharmaceuticals
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230620516360/en/
MedinCell David Heuzé Head of Communications
david.heuze@medincell.com +33 (0)6 83 25 21 86
NewCap Alban Dufumier / Louis-Victor Delouvrier Investor
Relations medincell@newcap.eu +33 (0)1 44 71 94 94
NewCap Nicolas Merigeau Media Relations medincell@newcap.eu +33
(0)1 44 71 94 94
Grafico Azioni Medincell (EU:MEDCL)
Storico
Da Mar 2024 a Mag 2024
Grafico Azioni Medincell (EU:MEDCL)
Storico
Da Mag 2023 a Mag 2024
